According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...

The U.S. Food and Drug Administration is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq ...

The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker ...

U.S. health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of ...

The United States Food and Drug Administration (FDA) has suspended the licence of one of the two chikungunya vaccines ...

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...

US health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of ...

Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...

Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S.

Investing.com -- Valneva SE ADR (NASDAQ:VALN) stock tumbled 20.4% premarket Monday after the U.S. Food and Drug ...

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for IXCHIQ ®, citing ...